This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
by Zacks Equity Research
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
SNYNegative Net Change BAYRYPositive Net Change LXRXPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
BSXPositive Net Change AMGNNegative Net Change DXCMNo Net Change ABBVNegative Net Change CTREPositive Net Change CHCTNegative Net Change
biotechnology biotechs healthcare medical medical-devices pharmaceuticals
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
by Zacks Equity Research
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
BMYNegative Net Change MRKNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
by Sundeep Ganoria
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs gene-editing gene-therapy medical messenger-rna
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
by Zacks Equity Research
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bristol Myers Collaborates With BNTX for Oncology Candidate
by Zacks Equity Research
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
NVSNegative Net Change BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
by Zacks Equity Research
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
GSKNegative Net Change GILDNegative Net Change MIRMNegative Net Change IMCRNegative Net Change
biotechs
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
by Zacks Equity Research
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
SNYNegative Net Change LXRXPositive Net Change AMRNNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
by Zacks Equity Research
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
AMGNNegative Net Change BAYRYPositive Net Change LXRXPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
by Zacks Equity Research
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
SNYNegative Net Change BAYRYPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results
by Zacks Equity Research
SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.
MRKNegative Net Change SMMTNegative Net Change TILNegative Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals
Implied Volatility Surging for Krystal Biotech Stock Options
by Zacks Equity Research
Investors need to pay close attention to KRYS stock based on the movements in the options market lately.
KRYSNegative Net Change
biotechnology biotechs medical
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
by Zacks Equity Research
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
NVSNegative Net Change PFENegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
by Ekta Bagri
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend investors remain on the sidelines at current levels.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
by Zacks Equity Research
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
REGNNegative Net Change LXRXPositive Net Change NTLANegative Net Change CMMBNegative Net Change
biotechs
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
by Zacks Equity Research
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
by Zacks Equity Research
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
BAYRYPositive Net Change LXRXPositive Net Change AMRNNegative Net Change IMVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
by Zacks Equity Research
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
JNJNegative Net Change BAYRYPositive Net Change AMRNNegative Net Change ORICNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
by Zacks Equity Research
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
BMYNegative Net Change BAYRYPositive Net Change LXRXPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
by Zacks Equity Research
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
GSKNegative Net Change AGENNegative Net Change ADPTPositive Net Change SPROPositive Net Change
biotechs medical pharmaceuticals
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
by Zacks Equity Research
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
MRNANegative Net Change AGENNegative Net Change ADPTPositive Net Change
biotechs medical messenger-rna vaccines
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
by Zacks Equity Research
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
LXRXPositive Net Change AMRNNegative Net Change CMMBNegative Net Change CADLNegative Net Change
biotechs
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
by Zacks Equity Research
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
NVONegative Net Change LLYNegative Net Change VRTXPositive Net Change
biotechs medical pharmaceuticals
RCKT Stock Tanks on Patient Death in Danon Disease Study
by Zacks Equity Research
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
LXRXPositive Net Change AMRNNegative Net Change RCKTNegative Net Change CMMBNegative Net Change
biotechs